NORCROSS, Ga., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that new preclinical data show its leading galectin-inhibiting drugs – GR-MD-02 and GM-CT-01 – demonstrate positive therapeutic effects on nonalcoholic steatohepatitis (NASH, or fatty liver disease) with fibrosis. Results were published in an article titled “Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors” in the peer-reviewed, open-access journal PLOS ONE.
Help employers find you! Check out all the jobs and
